Undisclosed CD3 Switch-DARPin T Cell Engager / Molecular Partners - LARVOL DELTA

The Company will present an update on the CD3 Switch-DARPin program at SITC in November 2025 (GlobeNewswire)

Preclinical • Oncology

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025 (GlobeNewswire) - "Preclinical proof-of-concept data on Molecular Partners’ conditionally activated CD3 Switch-DARPin shows it activates T cells specifically in the presence of cells co-expressing MSLN and epithelial cell adhesion molecule (EpCAM), increasing tumor specificity. Concurrent CD2 co-engagement leads to sustained T cell activation and cytotoxic capacity, preventing T cell dysfunction. The Switch-DARPin effectively induces significant tumor regression in mice engrafted subcutaneously with MSLN- and EpCAM-expressing cells, without signs of T cell activation in the periphery, indicating a favorable safety profile."

Preclinical • Oncology

CD3 Switch-DARPin: Preclinical proof-of-concept for T cell engager with enhanced function in solid tumors (GlobeNewswire) - "Posters will be presented at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)....This CD3 Switch-DARPin molecule effectively induces potent tumor regression in vivo, with reduced cytokine release, a significant toxicity event for TCEs in the clinic, compared to an unmasked CD3 with CD2 co-stimulation. In addition, co-engagement of CD2 leads to sustained T cell activation and cytotoxic capacity. Finally, masking of CD3 prevents T cell activation in the absence of tumor antigens, hence potentially allowing for 'silent' TCEs outside of tumors."

Preclinical • Solid Tumor